SILK News and Press, Silk Road Medical Inc. From 09/07/22

SUNNYVALE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced enrollment of the first patient in ROADSTER 3, the first prospective, multi-center, single-arm st...

SUNNYVALE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Morgan Stanley 20th Annual Global He...

Silk Road Medical, Inc. (SILK) Q2 2022 Earnings Conference Call July 26, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - President and Chief Executive Officer Lucas Buchanan - Chief Financial Officer and Chief Operating Offic...

The following slide deck was published by Silk Road Medical, Inc in conjunction with their 2022 Q2 earnings call. For further details see: Silk Road Medical, Inc 2022 Q2 - Results - Earnings Call Presentation

Silk Road Medical press release ( NASDAQ: SILK ): Q2 GAAP EPS of -$0.44 beats by $0.02 . Revenue of $33.17M (+25.4% Y/Y) beats by $2.14M . Silk Road Medical projects revenue for the full year 2022 to range from $128 million to $133 million, which represents 26%...

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...

Silk Road medical has printed a series of operating losses over the past 2 years to date. Investors have pushed away from rewarding top-line growth in FY22 and look to be agreeing with bottom-line fundamentals instead. In that vein, we see a lack of forward upside capture in SILK,...

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2022 after market close on Tuesday, July 26, 2022...

Citigroup downgraded medical device company Silk Road Medical ( NASDAQ: SILK ) to Sell from Neutral in a research note issued on Monday. The firm has a price target of $33, implying a downside risk of ~22% from stock's last close. Shares of SILK are down 4.8% to trade ...

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) --  Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgica...